Loading…

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease

Saved in:

Bibliographic Details
Published in:	Bone marrow transplantation (Basingstoke) 2019-05, Vol.54 (5), p.746-748
Main Authors:	Kaloyannidis, Panayotis, Shaibani, Eshrak Al, Apostolidis, Ioannis, Kanfar, Solaf, Anezi, Khalid Al, Hashmi, Hani Al
Format:	Article
Language:	English
Subjects:	Adult Antibodies Antineoplastic agents Bortezomib Bortezomib - administration & dosage Chronic Disease Clinical trials Correspondence Dosage and administration Drug therapy Drug Therapy, Combination Graft vs Host Disease - drug therapy Graft vs Host Disease - etiology Graft vs Host Disease - pathology Graft vs. host disease Graft-versus-host reaction Humans Lymphoma, T-Cell - therapy Male Medical research Monoclonal antibodies Morbidity Mortality Mycophenolate mofetil Nitriles Patient outcomes Pyrazoles - administration & dosage Pyrimidines Ruxolitinib Stem cell transplantation Stem cells Steroids Surgery
Citations:	Items that this one cites
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!